(Q36559277)

14 August 2017

1 reference

title

Male breast cancer: a gender issue (English)

1 reference

14 August 2017

1 reference

Zeina Nahleh

1

1 reference

14 August 2017

Saulius Girnius

series ordinal

2

1 reference

14 August 2017

publication date

1 August 2006

1 reference

Nature Clinical Practice Oncology

14 August 2017

published in

1 reference

14 August 2017

volume

3

1 reference

14 August 2017

issue

8

1 reference

14 August 2017

page(s)

428-437

1 reference

Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

21 January 2018

Breast cancer in men.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

Adjuvant Tamoxifen for male breast cancer (MBC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

Role of aminoglutethimide in male breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Breast carcinoma in men: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Is male breast cancer similar or different than female breast cancer?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Risk factors for male breast cancer--a case-control study from Scandinavia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Risk factors for male breast cancer (United States)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

BRCA2 germline mutations in male breast cancer cases and breast cancer families

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

The CAG repeat within the androgen receptor gene in male breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Androgen Receptor Gene Alterations in Finnish Male Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Androgen receptor gene mutation in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

A polymorphism in the CYP17 gene is associated with male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

CHEK2*1100delC and male breast cancer risk in Israel

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

CHEK2 1100delC is not a risk factor for male breast cancer population

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Male breast cancer: results of the treatments and prognostic factors in 397 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

A 50-year experience of male breast cancer: is outcome changing?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Breast cancer in the male: a report of 138 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma--a preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Expression of androgen receptor and prostate-specific antigen in male breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

The use of immunohistochemistry in metastatic prostatic adenocarcinoma to the breast

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Male breast cancer: Austrian experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Prognosis of breast cancer in males: an analysis of 170 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Carcinoma of the male breast: update 1994.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0564

1 reference

7 January 2021

Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0564

1 reference

7 January 2021

Carcinoma of the breast in males: a multiinstitutional survey

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Proliferative activity and steroid hormone receptor status in male breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Molecular markers in male breast carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Male breast cancer: a review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

A comparison outcome of male breast cancer with female breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Mutations of the p53 gene in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Angiogenesis in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0564

1 reference

7 January 2021

Sentinel node biopsy in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Sentinel node biopsy in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Efficacy of sentinel lymph node biopsy in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Adjuvant radiotherapy for breast carcinoma in men: a 20-year clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Cancer of the male breast; a report of 146 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Adjuvant chemotherapy in males with cancer of the breast

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Role of adjuvant chemotherapy in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Adjuvant systemic therapy for male breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Metastatic breast cancer in males. Assessment of endocrine therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Hormonal therapy for metastatic male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Hormonal treatment of disseminated male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Cyproterone acetate in advanced male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Tamoxifen in the treatment of male breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Efficacy of anastrozole in male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Complete remission obtained with letrozole in a man with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0564

7 January 2021

Identifiers

DOI

10.1038/NCPONC0564

1 reference

Dimensions Publication ID

14 August 2017

1036621287

0 references

1 reference